Abstract 1214P
Background
HRR gene alterations are enriched in prostate cancer (PC) and are associated with sensitivity to PARP inhibitors. Homozygous deletion (HD), which accounts for up to 15% of HRR gene alterations in PC, is an important type of pathogenic alteration. However, the reliable detection of HD is technically challenging. Here we introduced a novel machine learning based method for HD detection in formalin-fixed paraffin-embedded (FFPE) PC tissues.
Methods
HD/non-HD simulation events (∼30000) of varying tumor cellularity and fragment size were constructed using the sequencing data of matched tumor and wild type cell lines tested by AmoyDx HRD Complete NGS panel. Seven artificial features were calculated based on genomic segment depth and minor allele frequency of single nucleotide polymorphisms, tumor cellularity and tumor ploidy. The feature data were fed into the xgboost with 10-StratifiedKFold to generate HD recognition model (training :validation datasets=7:3). Analytical performance was assessed with reference cell lines: specificity with wildtype cell lines, sensitivity with gradient HD-positive cell lines (tumor cellularity: 20%, 30%, 40%, 50%) with varying DNA input (30ng, 50ng, 100ng), reproducibility of intra- and inter-runs, and anti-interference against hemoglobin, triglycerides, xylene, paclitaxel, and ethanol. Clinical performance was evaluated using FFPE PC tissues.
Results
The trained HD model achieved 99.8% accuracy in the in silico validation dataset. Analytical validation demonstrated: 100% specificity; 100% sensitivity at gene level with 30% tumor cellularity and at exon level with 40% tumor cellularity with 100ng DNA input; 100% reproducibility; strong anti-interference capability with all HD events detected and no false positives. 132 FFPE PC tissues showed high consistency with a second validated NGS assay (PPA 100%, NPA 98.4%, OPA 98.5%).
Conclusions
A machine learning based method was successfully developed and adopted in multiple NGS assays to detect HD of HRR genes in PC tissues. It provides a reliable approach to effectively identify PC patients with HRR HD.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Janssen.
Disclosure
J. Wang, P. Cheng, W. Xu, Z. Huang, X. Chen, S. Liu, Y. Guo, W. Shi, S. Yang: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics. X. Ye, U. Singh, K. Bell, K. Urtishak, L. Luo, X. Lyu, L. Zhou: Financial Interests, Institutional, Full or part-time Employment: Janssen Research & Development.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14